Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-center Phase II Clinical Study on MAX-40279-01 as Second or Later Lines of Treatment of Advanced Gastric Cancer or Gastroesophageal Junction Cancer

NCT05395780 is registered in ClinicalTrials.gov with Maxinovel Pty., Ltd. as lead sponsor.

NCT NCT05395780
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05395780 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-center Phase II Clinical Study on MAX-40279-01 as Second or Later Lines of Treatment of Advanced Gastric Cancer or Gastroesophageal Junction Cancer
Lead sponsor
Maxinovel Pty., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2022
Completion date
December 31, 2023
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, gastroesophageal junction cancer